Mortalité cardiovasculaire dans les syndromes de Cushing infracliniques

Translated title of the contribution: Cardiovascular mortality in patients with subclinical Cushing

Research output: Contribution to journalArticle

1 Citation (Scopus)

Abstract

Patients with adrenal incidentaloma (AI) and subclinical hypercortisolism (SH) show a high prevalence of cardiovascular risk factors and an increased prevalence and incidence of cardiovascular events. Furthermore, some recent data suggest that in these patients, the cardiovascular mortality is also increased. Unfortunately, to date, the diagnosis of SH is still a matter of debate, and, therefore, it is still not possible to address the treatment of choice (i.e. surgical or conservative approach) in many AI patients. Overall, the available data show that in AI patients with established SH the surgical removal of the adrenal mass causing SH can lead to the improvement of hypertension and diabetes, but in many patients with possible SH the effect of surgery is still largely unknown. Finally, no data are available on the effect of the recovery from SH on the cardiovascular events. Therefore, randomized studies are needed to investigate the possibility of predicting the usefulness of surgery by using the available indexes of cortisol secretion in the individual AI patient. Finally, the development of safe and well-tolerated drugs aimed to control cortisol secretion will be among the goals of the future research.

Original languageFrench
Pages (from-to)149-152
JournalAnnales d'Endocrinologie
Volume79
Issue number3
DOIs
Publication statusPublished - 2018

Fingerprint

Cushing Syndrome
Mortality
Hydrocortisone
Hypertension
Adrenal incidentaloma
Incidence
Pharmaceutical Preparations

Keywords

  • Adrenal incidentaloma
  • Cardiovascular mortality
  • Subclinical hypercortisolism

ASJC Scopus subject areas

  • Endocrinology, Diabetes and Metabolism
  • Endocrinology

Cite this

@article{4fbbe3973ebb4b5caf961a76414667ed,
title = "Mortalit{\'e} cardiovasculaire dans les syndromes de Cushing infracliniques",
abstract = "Patients with adrenal incidentaloma (AI) and subclinical hypercortisolism (SH) show a high prevalence of cardiovascular risk factors and an increased prevalence and incidence of cardiovascular events. Furthermore, some recent data suggest that in these patients, the cardiovascular mortality is also increased. Unfortunately, to date, the diagnosis of SH is still a matter of debate, and, therefore, it is still not possible to address the treatment of choice (i.e. surgical or conservative approach) in many AI patients. Overall, the available data show that in AI patients with established SH the surgical removal of the adrenal mass causing SH can lead to the improvement of hypertension and diabetes, but in many patients with possible SH the effect of surgery is still largely unknown. Finally, no data are available on the effect of the recovery from SH on the cardiovascular events. Therefore, randomized studies are needed to investigate the possibility of predicting the usefulness of surgery by using the available indexes of cortisol secretion in the individual AI patient. Finally, the development of safe and well-tolerated drugs aimed to control cortisol secretion will be among the goals of the future research.",
keywords = "Adrenal incidentaloma, Cardiovascular mortality, Subclinical hypercortisolism",
author = "Valentina Morelli and Maura Arosio and Iacopo Chiodini",
year = "2018",
doi = "10.1016/j.ando.2018.03.005",
language = "Francese",
volume = "79",
pages = "149--152",
journal = "Annales d'Endocrinologie",
issn = "0003-4266",
publisher = "Elsevier Masson",
number = "3",

}

TY - JOUR

T1 - Mortalité cardiovasculaire dans les syndromes de Cushing infracliniques

AU - Morelli, Valentina

AU - Arosio, Maura

AU - Chiodini, Iacopo

PY - 2018

Y1 - 2018

N2 - Patients with adrenal incidentaloma (AI) and subclinical hypercortisolism (SH) show a high prevalence of cardiovascular risk factors and an increased prevalence and incidence of cardiovascular events. Furthermore, some recent data suggest that in these patients, the cardiovascular mortality is also increased. Unfortunately, to date, the diagnosis of SH is still a matter of debate, and, therefore, it is still not possible to address the treatment of choice (i.e. surgical or conservative approach) in many AI patients. Overall, the available data show that in AI patients with established SH the surgical removal of the adrenal mass causing SH can lead to the improvement of hypertension and diabetes, but in many patients with possible SH the effect of surgery is still largely unknown. Finally, no data are available on the effect of the recovery from SH on the cardiovascular events. Therefore, randomized studies are needed to investigate the possibility of predicting the usefulness of surgery by using the available indexes of cortisol secretion in the individual AI patient. Finally, the development of safe and well-tolerated drugs aimed to control cortisol secretion will be among the goals of the future research.

AB - Patients with adrenal incidentaloma (AI) and subclinical hypercortisolism (SH) show a high prevalence of cardiovascular risk factors and an increased prevalence and incidence of cardiovascular events. Furthermore, some recent data suggest that in these patients, the cardiovascular mortality is also increased. Unfortunately, to date, the diagnosis of SH is still a matter of debate, and, therefore, it is still not possible to address the treatment of choice (i.e. surgical or conservative approach) in many AI patients. Overall, the available data show that in AI patients with established SH the surgical removal of the adrenal mass causing SH can lead to the improvement of hypertension and diabetes, but in many patients with possible SH the effect of surgery is still largely unknown. Finally, no data are available on the effect of the recovery from SH on the cardiovascular events. Therefore, randomized studies are needed to investigate the possibility of predicting the usefulness of surgery by using the available indexes of cortisol secretion in the individual AI patient. Finally, the development of safe and well-tolerated drugs aimed to control cortisol secretion will be among the goals of the future research.

KW - Adrenal incidentaloma

KW - Cardiovascular mortality

KW - Subclinical hypercortisolism

UR - http://www.scopus.com/inward/record.url?scp=85045020327&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85045020327&partnerID=8YFLogxK

U2 - 10.1016/j.ando.2018.03.005

DO - 10.1016/j.ando.2018.03.005

M3 - Articolo

AN - SCOPUS:85045020327

VL - 79

SP - 149

EP - 152

JO - Annales d'Endocrinologie

JF - Annales d'Endocrinologie

SN - 0003-4266

IS - 3

ER -